Prevalence of ROS1 Fusion in Chinese Patients With Non-Small Cell Lung Cancer

Thoracic Cancer - Australia
doi 10.1111/1759-7714.12899
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Wiley

Related search

Clinicopathological Features and Clinical Efficacy of Crizotinib in Chinese Patients With ROS1‑positive Non‑small Cell Lung Cancer

Oncology Letters
Cancer ResearchOncology
2019English

Crizotinib Improves Osteoarthritis Symptoms in a ROS1-Fusion Advanced Non–Small Cell Lung Cancer Patient

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2015English

HER2 Mutations in Chinese Patients With Non-Small Cell Lung Cancer

Oncotarget
Oncology
2016English

Clinical Features of Bim Deletion Polymorphism and Its Relation With Crizotinib Primary Resistance in Chinese Patients With ALK /ROS1 Fusion-Positive Non-Small Cell Lung Cancer

Cancer
Cancer ResearchOncology
2017English

ROS1 Immunohistochemistry Among Major Genotypes of Non–Small-Cell Lung Cancer

Clinical Lung Cancer
Cancer ResearchOncologyRespiratory MedicinePulmonary
2015English

P2.01-50 Thromboembolism in ROS1 Rearranged Non-Small Cell Lung Cancer

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

OA09 Preliminary Clinical Activity of Repotrectinib (TPX-0005) in Advanced ROS1 Fusion-Positive Non-Small Cell Lung Cancer

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

P1.03-02 Analysis of SMAD4 Aberrations in Chinese Patients With Non-Small-Cell Lung Cancer

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

Clinicopathological Characteristics and Survival of ALK, ROS1 and RET Rearrangements in Non-Adenocarcinoma Non-Small Cell Lung Cancer Patients

Cancer Biology and Therapy
Cancer ResearchOncologyMolecular MedicinePharmacology
2016English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy